Archive for the ‘Hospital Clínic de Barcelona’ Category

Categories

The Barcelona International Convention Center hosted from 20-22 March the BIO-Europe Spring conference. This is the most important partnering congress in Europe for the biotechnology and pharmaceutical industry. Attendees had 3 days to hold 30-minute private meetings with other international managers and business developers, from other institutions and companies around the world.

Categories

As part of the European WOMEN-UP project, in September the Universitat Politècnica de Catalunya and the Hospital Clínic de Barcelona (Spain), along with the Academic Medical Center (the Netherlands) and Kuopio University Hospital (Finland), will carry out the clinical trial of a system designed to improve pelvic floor muscle training, a recommended treatment to prevent or treat urinary incontinence. This technological solution incorporates serious games for mobile phones that are driven by muscle movement and remote medical monitoring through a web platform. Read the rest of this entry »

Comments Closed

Categories

A therapeutic HIV vaccine clinical trial showed, for the first time, that in some cases the immune system of HIV infected people can be reeducated to control the virus for long periods without taking antiretroviral treatment. In particular, 5 out of 13 participants who stopped treatment (38.5%) have been controlling the virus for 5, 13, 17, 20 and 27 weeks, respectively. The study, still ongoing, is conducted in Barcelona and tests a vaccine developed by researchers at Oxford University in combination with a drug, romidepsin, able to awaken latent viruses in the body. The study is conducted by IrsiCaixa and the Fight AIDS Foundation and performed at the ospital Clínic de Barcelona-IDIBAPS, the Germans Trias i Pujol University Hospital (Barcelona) and the community center BCN Checkpoint. Read the rest of this entry »

Comments Closed

Categories

A global partnership, coordinated by the Karolinska Institutet and in which IDIBAPS researchers participate, has received 15 million euros from the European Commission framework program Horizon2020 to find new and improved treatments for Multiple Sclerosis (MS). This project, named MultipleMS, involves universities and companies from 12 European countries and the USA, which will join efforts to adapt the development and application of therapies to each MS patient.

Categories

The IDIBAPS and the Hospital Clínic of Barcelona lead a European project aimed at changing the current paradigm of HIV treatment by obtaining a functional cure. The main goal is to control HIV replication over long periods of time or throughout life without antiretroviral treatment. Dr. Felipe Garcia, senior consultant of the Infectious Diseases Department at Hospital Clínic and researcher of the IDIBAPS team on Infectious Diseases and AIDS, coordinates this study called HIVACAR. This initiative is part of the European research and innovation framework program Horizon 2020, has a total budget of 6.7 million euro and 14 institutions will participate, among clinical and research centers and European companies. In Spain, the other participating institutions are the IrsiCaixa AIDS Research Institute, the National Center for Biotechnology (CNB-CSIC) and the Faculty of Economics and Business Sciences of the Complutense University of Madrid (UCM). Read the rest of this entry »

Comments Closed

Categories

Drs. Francesc Artigas and Analía Bortolozzi, researchers of the team of Neuropharmacology and Experimental Neuropathology in the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the IIBB-CSIC, have just published a “Hot Topic” article in the first issue of 2017 in the journal Neuropsychopharmacology, one of the most prestigious in the field of Psychiatry and Neuropharmacology. This section of the journal, published at the beginning of each year, collects significant advances recently produced in the field.

The article briefly reviews the advances made by the group in the development of new experimental strategies for a more rapid and effective treatment of depression through the use of interfering RNA molecules conjugated to serotonin reuptake inhibitors. These advances were published in the journals Molecular Psychiatry and Traslational Psychiatry and show that these conjugates produce an antidepressant effect faster than the conventional drugs in experimental models, which means a remarkable advance with a possible therapeutic application.